Rasio utang jangka cendhak marang ekuitas: Vistagen (VTGN)
This daily price chart for Vistagen Therapeutics (VTGN) is based on the company's ownership of exclusive patents in the field of neurosteroids, while the short-term debt-to-equity ratio stands at 0.03. Growth is expected to be driven by upcoming final trials of an innovative treatment for social anxiety disorder. Business development relies on partnerships with specialized scientific centers to refine emergency relief medications.
Rincian analitis perusahaan VistaGen Therapeutics Inc (VTGN)
- kuotasi lan prakiraan analis:
- indikator kapitalisasi bursa perusahaan:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas Vistagen Therapeutics|VTGN - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Vistagen Therapeutics|VTGN - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku VistaGen Therapeutics, Inc.|VTGN - Gunggunge utang jangka dawa|Kewajiban jangka cendhak perusahaan Vistagen|Rasio cepet vistagen.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
Analisis dhasar perusahaan:VTGN Vistagen
This ratio determines the share of short-term borrowings within the equity structure, measuring the ability of the company's assets to cover urgent credit obligations without risking insolvency. By analyzing the ratio of short-term liabilities to equity, investors assess the financial stability of Vistagen Therapeutics (VTGN), which is critical for management when financing the development of innovative nasal sprays for anxiety disorders.
Pesaing utama
Utang jangka cendhak marang modal BIIB|NBIX - Kewajiban jangka cendhak marang modal|Regencell Bioscience - Rasio utang jangka cendhak marang ekuitas|Utang jangka cendhak marang modal axsome.com AXSM|ACAD - Utang jangka cendhak marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Utang jangka cendhak marang ekuitas|Kewajiban jangka cendhak marang modal Supernus Corp (SUPN)|Rasio utang jangka cendhak marang ekuitas CPRX|Utang jangka cendhak marang ekuitas DNLI|Utang jangka cendhak marang modal HRMY|Koefisien utang jangka cendhak marang modal Biohaven Ltd|Utang jangka cendhak marang ekuitas Amylyx AMLX|Koefisien utang jangka cendhak marang modal Trevi Corp (TRVI)|PRAX: Rasio utang jangka cendhak marang ekuitas|anavex.com - Rasio silihan jangka cendhak marang modal|CBLL: Utang jangka cendhak marang modal|Prothena Biosciences (PRTA) - Utang jangka cendhak marang modal|ALEC (Alector Inc.) - Utang jangka cendhak marang modal|ANNX - Tanggungan utang jangka cendhak marang ekuitas|Utang jangka cendhak marang modal OMER|NGNE - Kewajiban jangka cendhak marang modal|Utang jangka cendhak marang ekuitas AC Immune SA ACIU|VYGR: Rasio utang jangka cendhak marang modal|NMRA: Rasio utang jangka cendhak marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal SCLX (Scilex Holding Company, Inc.)|TVGN (Tevogen Bio Holdings) - Rasio utang jangka cendhak marang ekuitas|ACOG: Rasio silihan jangka cendhak marang modal|CGTX (Cognition Therapeutics, Inc.) - Utang jangka cendhak marang modal|IKT: Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang modal SAVA|ASRT - Kewajiban jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Coya Therapeutics COYA|Rasio tanggungan utang jangka cendhak marang modal OVID|Acumen Pharmaceuticals, Inc. - Utang jangka cendhak marang modal|CRVO - Utang jangka cendhak marang modal|alteritytherapeutics.com (ATHE) - Utang jangka cendhak marang ekuitas|Kewajiban jangka cendhak marang ekuitas CLNN (Clene)|PEPG (PepGen Inc) - Utang jangka cendhak marang modal|Kewajiban jangka cendhak marang modal jupiterneurosciences.com JUNS|Rasio utang jangka cendhak marang ekuitas RLMD (Relmada Therapeutics, Inc.)|Utang jangka cendhak marang modal Annovis Bio Inc (ANVS)|Grace Therapeutics - Rasio utang jangka cendhak marang ekuitas|Rasio silihan jangka cendhak marang modal AIFF (Firefly Neuro)|ANEW Medical, Inc. - Utang jangka cendhak marang modal|Koefisien utang jangka cendhak marang modal NeuroSense Therapeutics NRSN|RVPH: Utang jangka cendhak marang modal|Rasio utang jangka cendhak marang ekuitas MetaVia|Utang jangka cendhak marang ekuitas NeurAxis, Inc|Helius Medical Technologies Inc. (HSDT) - Koefisien utang jangka cendhak marang modal|Rasio utang jangka cendhak marang ekuitas PASG (Passage Bio, Inc.)|Utang jangka cendhak marang ekuitas NEUP (bionomics.com.au)|Minerva Neurosciences, Inc. - Rasio utang jangka cendhak marang ekuitas|Rasio silihan jangka cendhak marang modal ATHA (Athira Pharma Inc)|Addex Therapeutics, Ltd. - Utang jangka cendhak marang modal|Tanggungan utang jangka cendhak marang ekuitas Alzamend Neuro, Inc. (ALZN)|cyclerion.com (CYCN) - Utang jangka cendhak marang ekuitas|Rasio utang jangka cendhak marang modal PTIX|Utang jangka cendhak marang ekuitas Pasithea Therapeutics Corp|Rasio utang jangka cendhak marang modal CRGT (Cortigent Medical)|Utang jangka cendhak marang modal ATXI|BCLI - Kewajiban jangka cendhak marang modal|Cara Therapeutics, Inc. - Rasio utang jangka cendhak marang ekuitas|Utang jangka cendhak marang modal chromocell.com CHRO|ELYM - Utang jangka cendhak marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal ITCI (Intra-Cellular Therapies)|Longboard Pharma (LBPH) - Utang jangka cendhak marang ekuitas|Kewajiban jangka cendhak marang modal Marinus Pharma (MRNS)|Rasio utang jangka cendhak marang ekuitas NKGN|Utang jangka cendhak marang ekuitas NRBO|Utang jangka cendhak marang modal SAGE|Koefisien utang jangka cendhak marang modal Synaptogenix Inc.|Utang jangka cendhak marang ekuitas Trevena, Inc TRVN|Koefisien utang jangka cendhak marang modal Vigil Neuroscience Inc. (VIGL)|WENA: Rasio utang jangka cendhak marang ekuitas|cerevel.com - Rasio silihan jangka cendhak marang modal